Table 1.

Patient and disease characteristics

IDAge (y)GenderHistologyBone metsLiver metsIMDC risk groupPrior nephrectomy
168MClear cellNoYesIntermediateYes
266MClear cell, sarcomatoid featuresNoNoIntermediateYes
359MClear cellNoNoPoorYes
469MClear cellNoNoFavorableYes
524MTranslocationNoNoIntermediateYes
659MClear cellYesNoPoorNo
772MClear cell, sarcomatoid featuresYesNoPoorYes
868FClear cellNoNoFavorableYes
975MClear cell, with chromophobe featuresNoYesFavorableYes
1075MClear cellYesNoPooraYes
1168MClear cellNoNoIntermediateYes
1277FClear cellNoYesIntermediateYes
1368MClear cellNoNoIntermediateYes
1479MClear cellNoNoIntermediateYes
1575FClear cellNoYesIntermediateaYes
1668FClear cellNoNoFavorableYes
1766FClear cell, sarcomatoid featuresNoNoIntermediateYes
1865MClear cellNoNoPoorYes
1966MClear cellNoNoIntermediateYes
  • Abbreviations: M, male; F, female, Mets, metastasis; IMDC, International Metastatic Renal Cell Carcinoma Database Consortium.

  • aIMDC risk group determined at the start of anti–PD-1/PD-L1 therapy due to lack of clinical information regarding the IMDC prognostic criteria at diagnosis.